Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.54 USD
Change Today -0.02 / -0.56%
Volume 10.2K
CDXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 11:56 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Open
$3.55
Previous Close
$3.56
Day High
$3.63
Day Low
$3.54
52 Week High
04/15/15 - $5.65
52 Week Low
10/2/14 - $2.05
Market Cap
142.5M
Average Volume 10 Days
54.8K
EPS TTM
$-0.39
Shares Outstanding
40.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services and enzyme optimization services; and supplies enzymes, pharmaceutical intermediates, and active pharmaceutical ingredients. In addition, the company develops biocatalysts for use in the fine chemicals market, including food, animal feed, agricultural chemicals, and flavors and fragrances. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

91 Employees
Last Reported Date: 03/6/15
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $171.9K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $385.4K
Senior Vice President of Research & Developme...
Total Annual Compensation: $257.4K
Compensation as of Fiscal Year 2014.

codexis inc (CDXS) Key Developments

Codexis, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Codexis, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. The company reported total revenues for the quarter ended June 30, 2015 were $6.0 million compared with $6.6 million for the second quarter of 2014. Net loss was $5.4 million, or $0.14 per share, improved from a net loss of $8.5 million, or $0.22 per share, for the second quarter of 2014. The non-GAAP adjusted net loss for the second quarter of 2015 was $2.7 million, or $0.07 per share, compared with a non-GAAP adjusted net loss of $2.6 million, or $0.07 per share, for the second quarter of 2014. Loss from operations was $5.698 million against $8.911 million a year ago. Loss before income taxes was $5.790 million against $8.916 million a year ago. The company reported net loss for the first six months of 2015 of $10.9 million, or $0.28 per share, compared favorably with a net loss of $14.9 million, or $0.39 per share, for the first six months of 2014. The non-GAAP adjusted net loss for the first six months of 2015 was $5.6 million, or $0.14 per share, an improvement over the non-GAAP adjusted net loss of $6.7 million, or $0.18 per share, for the same period last year. Total revenues were $12.816 million against $13.644 million a year ago. Loss from operations was $11.227 million against $15.307 million a year ago. Loss before income taxes was $11.340 million against $15.421 million a year ago. The company now expects total revenues for 2015 to be between $41 million and $44 million, representing growth of 16% to 25% over 2014. This compares favorably with prior guidance of total revenues for 2015 of $39 million to $42 million. The company now expects gross margin as a percentage of total revenues to be 75% to 80%, an increase from previous guidance of 70% to 75%. The increase in gross margin guidance reflects improved sales mix and the impact of expected upfront and milestone payments under the company's non-exclusive licensing agreements in the second half of 2015.

Codexis Enters R&D Collaboration with a Global Biopharmaceutical Company

Codexis has entered into a collaborative research and development agreement with an undisclosed global biopharmaceutical company. As per the agreement, Codexis will employ CodeEvolver to develop a novel enzyme for use in its partner's preclinical therapeutic development program. In exchange, Codexis has received a $1 million upfront payment and will generate research and development service revenues relating to the stages of the program's enzyme development.

Codexis, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Codexis, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $3.54 USD -0.02

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €71.35 EUR +0.59
Cambrex Corp $45.93 USD -0.03
Koninklijke DSM NV €46.61 EUR +0.97
Novozymes A/S kr294.20 DKK +6.40
Takasago International Corp ¥618.00 JPY +3.00
View Industry Companies
 

Industry Analysis

CDXS

Industry Average

Valuation CDXS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit www.codexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.